key: cord-0299560-ml8arkpd
authors: Peacock, Thomas P.; Brown, Jonathan C.; Zhou, Jie; Thakur, Nazia; Sukhova, Ksenia; Newman, Joseph; Kugathasan, Ruthiran; Yan, Ada W.C.; Furnon, Wilhelm; De Lorenzo, Giuditta; Cowton, Vanessa M.; Reuss, Dorothee; Moshe, Maya; Quantrill, Jessica L.; Platt, Olivia K.; Kaforou, Myrsini; Patel, Arvind H.; Palmarini, Massimo; Bailey, Dalan; Barclay, Wendy S.
title: The altered entry pathway and antigenic distance of the SARS-CoV-2 Omicron variant map to separate domains of spike protein
date: 2022-05-13
journal: bioRxiv
DOI: 10.1101/2021.12.31.474653
sha: 4a7091e3293e1b2a201d27ff2f9c27547bc13c46
doc_id: 299560
cord_uid: ml8arkpd

The SARS-CoV-2 Omicron/BA.1 lineage emerged in late 2021 and rapidly displaced the Delta variant before being overtaken itself globally by, the Omicron/BA.2 lineage in early 2022. Here, we describe how Omicron BA.1 and BA.2 show a lower severity phenotype in a hamster model of pathogenicity which maps specifically to the spike gene. We further show that Omicron is attenuated in a lung cell line but replicates more rapidly, albeit to lower peak titres, in human primary nasal cells. This replication phenotype also maps to the spike gene. Omicron spike (including the emerging Omicron lineage BA.4) shows attenuated fusogenicity and a preference for cell entry via the endosomal route. We map the altered Omicron spike entry route and partially map the lower fusogenicity to the S2 domain, particularly the substitution N969K. Finally, we show that pseudovirus with Omicron spike, engineered in the S2 domain to confer a more Delta-like cell entry route retains the antigenic properties of Omicron. This shows a distinct separation between the genetic determinants of these two key Omicron phenotypes, raising the concerning possibility that future variants with large antigenic distance from currently circulating and vaccine strains will not necessarily display the lower intrinsic severity seen during Omicron infection.

that Omicron is attenuated in a lung cell line but replicates more rapidly, albeit to lower peak 21 titres, in human primary nasal cells. This replication phenotype also maps to the spike gene. 22 Omicron spike (including the emerging Omicron lineage BA.4) shows attenuated fusogenicity 23 and a preference for cell entry via the endosomal route. We map the altered Omicron spike 24 entry route and partially map the lower fusogenicity to the S2 domain, particularly the 25 substitution N969K. Finally, we show that pseudovirus with Omicron spike, engineered in the 26 S2 domain to confer a more Delta-like cell entry route retains the antigenic properties of 27 Omicron. This shows a distinct separation between the genetic determinants of these two key 28 Omicron phenotypes, raising the concerning possibility that future variants with large 29 antigenic distance from currently circulating and vaccine strains will not necessarily display 30 the lower intrinsic severity seen during Omicron infection. 31 Summary 32 The second year of the SARS-CoV-2 pandemic was marked by the repeated emergence 33 of SARS-CoV-2 variants with altered antigenicity, and/or enhanced transmissibility. The fifth 34 Variant Of Concern (VOC), Omicron, was first detected in Southern Africa 1 . Within just a 35 month of its initial detection, Omicron had spread to account for the majority of SARS-CoV-2 36 cases globally 2 . The major Omicron lineages, BA.1 and BA.2 (as well as the emerging Omicron 37 lineages BA.4 and BA.5), are marked by a total of >50 mutations across the entire genome, 38 including an unprecedented >25 mutations in the spike glycoprotein gene 1,3,4 . The large 39 antigenic distance between Omicron and the early pandemic spike protein correlates with a 40 loss of neutralization titre, a lower vaccine effectiveness against Omicron, and a high 41 frequency of reinfections 2,3,5-14 . 42 Infections with Omicron lineage viruses have resulted in a reduction in disease severity 43 relative to the previous VOC, Delta, including in those previously uninfected, or unvaccinated 44 individuals 15, 16 . Omicron lineage isolates also show a lower intrinsic severity than previous 45 VOCs in rodent models such as hamsters [17] [18] [19] [20] . In ex vivo systems, Omicron shows attenuated 46 replication in human cells derived from the lower respiratory tract but rapid replication in 47 upper airway epithelia 21, 22 . In vitro, Omicron does not induce syncytia, and the spike protein 48 has low fusogenicity 12,19,23 . Syncytia have been reported at autopsy of COVID cases, and the 49 efficient cleavage at the S1/S2 FCS in spike protein that underlies syncytia formation has been 50 associated with enhanced disease severity in animal models 28, 30, 31 . Furthermore, Omicron has 51 the ability to enter cells efficiently through the endosomal pathway compared to previous 52 variants 12, 19, 21, 23 . It is likely that these phenotypic properties are linked, and that cell entry 53 route and fusogenicity are indicators/surrogates for severity. 54 Here we map the molecular basis of lower severity in vivo to the Omicron spike gene. 55 We find that the Omicron spike confers attenuated replication in Calu-3 lung cells, due to 56 endosomal restriction. However Omicron spike confers rapid replication in primary human 57 nasal epithelial cultures, where endosomal restriction is less potent. Using chimeric and 58 mutant recombinant spike proteins, we demonstrate that a single substitution in the S2 59 domain of Omicron spike, N969K, confers endosomal entry and leads to lower fusogenicity. 60 Importantly, this means that the determinants of the cell entry pathway of Omicron (S2 61 domain) are distinct from those that confer its extreme antigenic distance (S1 domain). Thus, 62 we emphasize that future variants with a similar antigenic distance to Omicron but no 63 reduction in intrinsic severity could arise. 64 

The Omicron variants BA.1 and BA.2 show lower pathogenicity in a hamster model 66 To compare the intrinsic virulence of Omicron isolates with previous variants in vivo, 67 we inoculated groups of at least 4 naïve hamsters intranasally with SARS-CoV-2 variants - showed similar weight loss and shedding to the full isolates. This suggests that the 88 pathogenicity phenotype maps largely to the spike gene in the hamster model ( Figure 1C , 89 Extended data Figure 1C ). Animals infected with the BA.1 spike chimera lost marginally, 90 though not significantly, more weight and shed significantly higher titres of infectious virus 91 than the full BA.1 infected animals on days 1-3 post-inoculation, suggesting that viral genes 92 other than spike may contribute to the attenuated pathogenicity phenotype of Omicron 93 ( Figure 1C , Extended data Figure 1C ). Omicron is attenuated for replication in Calu-3 lung cells but replicates more rapidly than 119 We also performed mixed competition assays in Vero-AT cells, Calu-3 cells or hNECs. 120 Genome to RNA ratios of the two variants were measured over time following the inoculation 121 of a 50:50 mix using a variant-specific PCR protocol (see Extended data Figure Figure 2B ). 127 We further compared the replication of Omicron/BA.1 and BA.2 isolates in hNECs and 128 found BA.2 displayed the same initially rapid replication peaking at 24 hours (Extended data 129 Figure 2C ). In a direct competition assay between BA.1 and BA.2 in hNECs, neither virus 130 outgrew the other, although BA.2 genome copies trended higher over the first 48 hours post-131 infection (Extended data Figure 2D ). To assess the role of the spike gene in determining the cell type-specific differences in 135 replication between Omicron and Delta, we measured replication kinetics of the recombinant 136 viruses that varied only in spike and compared them to their parental whole virus isolates. 137 Each chimeric virus recapitulated the pattern of its spike donor parent, suggesting the spike 138 gene is the major determinant of the attenuated replication of BA.1 in Calu-3 cells and its 139 more rapid, but truncated, replication in hNEC cultures ( Figure 2C , Extended data Figure 2E ). To mediate cell entry, spike protein must be activated through cleavage at the S2' site 173 by cellular proteases in order to enable fusion between the viral and host cell membranes. 174 Ourselves and others have previously shown that, due to the presence of a furin cleavage site 175 (FCS) at the S1/S2 junction, SARS-CoV-2 virions emerge from producer cells already primed 176 for S2' cleavage, and gain a replication and transmission advantage by rapidly entering airway 177 cells at the cell surface or early endosome in a TMPRSS2-dependent manner 24,27 . A by-product 178 of this fusion at the cell surface is syncytium formation, which is hypothesised to be correlated 179 to disease severity 28-31 . 180 Omicron has been shown to lack the fusogenicity of previous variants such as 181 Delta 12,19,23 . Indeed, we observe that infection of Vero-AT cells with 2 independent isolates of Figure 5A ). 213 Single cell sequencing analysis of upper airway cells reveal there are approximately 214 twice as many cells that are ACE2 + /TMPRSS2than are ACE2 + /TMPRSS2 + (Supplementary   215   Table S1 ) 32-37 . We considered whether the early replication advantage of Omicron in the hNEC 216 was conferred by an expansion of the number of target cells available for initiation of 217 infection, as the endosomal pathway enables ACE2 + /TMPRSS2cells to be infected. We 218 modelled the comparative entry routes (Camostat sensitive vs Camostat insensitive) and 219 established the enhanced that endosomal entry of Omicron cannot account for the more 220 rapid replication in hNECs. Instead, Omicron appears to also use the TMPRSS2-dependent 221 route more efficiently than Delta in this cell type (Supplementary Table S2 Figure 4E ). 291 The rapid spread of Omicron can be accounted for by a combination of a potential 292 increase in inherent transmissibility, but also a large antigenic distance from previous variants 293 and the spike protein of the vaccines that have now been widely used, allowing frequent re-294 13 infections and vaccine-breakthrough infections 42 . The antigenic determinants of spike protein 295 have been mapped largely to the S1 domain, with epitopes both in the NTD and the RBD 43 . 296 To demonstrate that the antigenicity of the S1/S2 chimeras was determined by the sequence 297 in S1, we performed PV neutralisation assays with post-second dose vaccine antisera ( Figure   298 4F). As expected, the S2 domain had no effect on the antigenic properties of the spike 299 proteins, confirming that the entry/fusion phenotype and the antigenic phenotypes of 300 Omicron map to discrete spike substitutions. expressing different viral glycoproteins into Caco-2 the serine protease inhibitor, camostat (green), or 308 the cathepsin inhibitor, E64-d (pink). Assays were performed in triplicate. Data shown are the means 309 + s.d from four independent repeats (n = 4). All data were normalized to no drug control (grey). Omicron has shown one of the most rapid global takeovers of any SARS-CoV-2 variant 322 to date. Its rapid growth derives from a combination of partial escape from prior immunity, 323 and the phasing out of non-pharmaceutical interventions in many countries that coincided 324 with its emergence. Omicron appears to be inherently more transmissible than previous 325 variants 42 , with a shorter serial interval than Delta, but is also associated with less severe 326 disease. A key issue is to establish whether these three traits of antigenic distance, high 327 transmissibility and lower severity are linked, and this would have the implication of an 328 inevitable attenuation of severity for future variants. Here, we attribute these phenotypes to 329 distinct regions within the spike gene, suggesting they are likely to diverge as the virus 330 continues to evolve beyond Omicron. 331 We show that the altered entry route of Omicron is partly conferred by substitutions 332 in the S2 domain, particularly the substitution N969K that likely stabilises the interactions 333 between protomers and hinders fusion 39 . This slows altered entry and reduces cell surface 334 fusion, a process that has been linked with disease severity. Lack of syncytia formation by 335 Omicron, despite high ACE2 receptor binding and efficient S1/S2 cleavage, may be accounted Omicron virus were isolated by inoculating 100 µL of neat swab material onto Vero E6-ACE2-TMPRSS2 406 cells, incubating at 37 o C for 1 h before replacing with growth media supplemented with 1 x 407 penicillin/streptomycin and 1 x amphotericin B. Cells were incubated for 5-7 days until cytopathic 408 effect was observed. Isolates were passaged a further two times in Vero E6-ACE2-TMPRSS2 cells 48 Virus growth kinetics and competition assays were performed as described previously 24 For SARS-CoV-2 plaque assays, serial dilutions of virus supernatant in serum-free DMEM, 1% 417 NEAA and 1% P/S were performed and inoculated onto VAT cells for 1 h at 37 °C. Inoculum was then 418 removed and replaced with SARS-CoV-2 overlay medium (1 × MEM, 0.2% w/v BSA, 0.16% w/v 419 NaHCO3, 10 mM HEPES, 2 mM L-Glutamine, 1 × P/S, 1% w/v Avicel). Plates were incubated for 3 days 420 at 37 °C before overlay was removed and cells were stained for 1 h at room temperature in 2 x crystal 421 violet solution. 422

Reverse genetics derived viruses were generated as previously described 12,52,53 . Briefly, 423 recombinant SARS-CoV-2 Wuhan cDNA genomes bearing the D614G, or Delta spike-or Omicron spike-424 encoding sequence were generated from a set of relevant overlapping genomic cDNA fragments and 425 assembled using the Transformation-Associated Recombination (TAR) in yeast method as described 12 . 426

The assembled genomes were then used as a template to in vitro transcribe viral genomic RNA which 427 was then transfected into BHK-hACE2-N cells stably expressing the SARS-CoV-2 N and human ACE2 428 gene 48 for virus rescue. The rescued viruses were passaged once (P1 stock) in VERO E6 cells and their 429 full genomes sequenced using Oxford Nanopore as previously described 54 , to confirm the presence 430 of the desired mutations and exclude the presence of other spurious mutations. 431

Spike-encoding pcDNA3.1 plasmids were generated by mutagenesis or by gene synthesis as 433 described elsewhere 5,49 . Pseudovirus was generated and concentrated as previously described 24 Virus or pseudovirus concentrates were lysed in 4x Laemmli buffer (Bio-rad) with 10% β-482 mercaptoethanol and run on SDS-PAGE gels. After semi-dry transfer onto nitrocellulose membrane, 483 samples were probed with mouse anti-p24 (abcam; ab9071) and rabbit anti-SARS spike protein 484 (NOVUS; NB100-56578) or rabbit anti-S1 spike protein (SinoBiological; 40591-T62). Near infra-red 485 (NIR) secondary antibodies, IRDye® 680RD Goat anti-mouse (abcam; ab216776) and IRDye® 800CW 486

Goat anti-rabbit (abcam; ab216773) were subsequently used to probe membranes. Western blots 487 were visualised using an Odyssey DLx Imaging System (LI-COR Biosciences). 488

Virus genomes were quantified by E gene RT-qPCR as previously described 57 To measure the proportions of Omicron and Delta RNA from mixed samples a modified RT-497 qPCR protocol was developed using probes specific for the S gene of Omicron or Delta variants. 498

Flanking primers that were able to recognise a region of both Delta and Omicron were used (Forward: 499 TGGACCTTGAAGGAAAACAGGG and Reverse: TGGTTCTAAAGCCGAAAAACCC). A pair of probes were 500 then designed -a FAM probe specific to a 9 base pair insertion/deletion in the Omicron S gene at 501 amino acid position 214 (TTATAGTGCGTGAGCCAGAAGA), and a HEX probe specific to the same region 502 of the Delta S gene sequence lacking this insertion/deletion (CTATTAATTTAGTGCGTGATCT). 503

Alternatively, a second HEX probe was designed specific to this region of BA.2, which also lacks the 504 BA.1-specific insertion/deletion but has a SNP in this region (CTATTAATTTAGGGCGTGATCT). Reactions 505 were run on AgPath RT-PCR (Life Technologies) kit on a QuantStudio™ 7 Flex Real-Time PCR System 506 and the relative amounts of FAM and HEX signal used to determine the proportion of Omicron and 507 Delta in the original samples. Validation of the assay was carried out by extracting RNA from pure 508

Omicron and Delta supernatants, normalising by E gene copies and mixing at different ratios before 509 measuring using the assay. 510

To quantify the efficiency with which Omicron and Delta enter hNECs by either the endosomal 512 or TMPRSS2 pathway, we fitted a mathematical model to the data where hNECs were untreated or 513 pretreated with Camostat, and then infected with Omicron or Delta. The mathematical model 514 included the following processes: virus entry through either the TMPRSS2 or endosomal pathway; the 515 eclipse phase until virus production; virus production; loss of virus infectivity; and infected cell death. 516

The model assumed that the entry efficiency by the TMPRSS2 pathway was reduced to 0 in the 517 presence of Camostat. Only ACE2 + cells could become infected by the endosomal pathway, and only 518 ACE2 + TMPRSS2 + cells could become infected by the TMPRSS2 pathway. The proportion of ACE2 + and 519 ACE2 + TMPRSS2 + cells were taken from Supplementary Table 1. The model assumed that the entry 520 efficiency and eclipse phase duration could be different between the two pathways, and that the 521 eclipse phase duration for the endosomal pathway was shorter or equal to that of the TMPRSS2 522 pathway. All model parameters were allowed to vary between virus strains. Please see 523

Supplementary Methods for mathematical models and additional results. 

Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern 555

Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. 558

Continued Emergence and Evolution of Omicron in South Africa: New BA.4 560 and BA.5 lineages. medRxiv

Neutralising antibody activity against SARS-CoV-2 variants, including 563 Omicron, in an elderly cohort vaccinated with BNT162b2. medRxiv

The Omicron variant is highly resistant against antibody-mediated 566 neutralization -implications for control of the COVID-19 pandemic

Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic 569 shift

Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. 571

Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies

SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from 575 neutralizing antibody responses

Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. 578

SARS-CoV-2 Omicron is an immune escape variant with an altered cell 580 entry pathway. Nature Microbiology In press

Report 49 -Growth, population distribution and immune escape of 583 Omicron in England

Increased risk of SARS-CoV-2 reinfection associated with emergence of 585 Omicron in South Africa

Comparative analysis of the risks of hospitalisation and death associated 587 with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort 588 study

Early assessment of the clinical severity of the SARS-CoV-2 omicron variant 590 in South Africa: a data linkage study

SARS-CoV-2 Omicron virus causes attenuated disease in mice and 593 hamsters

Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron. 595

Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant

Characterization and antiviral susceptibility of SARS-CoV-2 Omicron/BA.2

SARS-CoV-2 Omicron variant replication in human bronchus and lung ex 601 vivo

The spike gene is a major determinant for the SARS-CoV-2 Omicron-BA.1 603 phenotype. bioRxiv

Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts tropism and 605 fusogenicity

The furin cleavage site in the SARS-CoV-2 spike protein is required for 607 transmission in ferrets

Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals 609 Constraints on Folding and ACE2 Binding

Molecular basis of receptor binding and antibody neutralization of Omicron. 612

Cleavage Site in the Spike 614 Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells

Drugs that inhibit TMEM16 proteins block SARS-CoV-2 spike-induced syncytia. 617

SARS-CoV-2 spike protein dictates syncytium-mediated lymphocyte 619 elimination

Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R 622 mutation

Furin Cleavage Site Is Key to SARS-CoV-2 Pathogenesis. bioRxiv

Single-cell meta-analysis of SARS-CoV-2 entry genes across tissues and 626 demographics

scRNA-seq assessment of the human lung, spleen, and esophagus tissue 628 stability after cold preservation

Single-cell RNA sequencing reveals profibrotic roles of distinct 631 epithelial and mesenchymal lineages in pulmonary fibrosis

A Single-Cell Atlas of the Human Healthy Airways

Immune cell residency in the nasal mucosa may partially explain respiratory 636 disease severity across the age range

Impaired local intrinsic immunity to SARS-CoV-2 infection in severe 639 COVID-19

The polybasic cleavage site in the SARS-CoV-2 spike modulates viral 641 sensitivity to Type I interferon and IFITM2

Structural basis of SARS-CoV-2 Omicron immune evasion and receptor 643 engagement

SARS-CoV-2 Spike evolution influences GBP and IFITM sensitivity. bioRxiv

Intrinsic furin-mediated cleavability of the spike 647

S1/S2 site from SARS-CoV-2 variant B.1.529 (Omicron). bioRxiv, 2022

SARS-CoV-2 Omicron VOC Transmission in Danish Households. medRxiv

N-terminal domain antigenic mapping reveals a site of vulnerability for 652 SARS-CoV-2

Respiratory epithelial cell responses to 654 SARS-CoV-2 in COVID-19

Rapid characterization of a Delta-Omicron SARS-CoV-2 recombinant 656 detected in Europe

Virological characteristics of SARS-CoV-2 BA.2 variant. bioRxiv

Identification of a Novel SARS-CoV-2 Delta-Omicron Recombinant Virus in 660 the United States. bioRxiv

A plasmid DNA-launched SARS-CoV-2 reverse genetics system and 662 coronavirus toolkit for COVID-19 research

Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate 665 induces high neutralizing antibody titers in mice

Increased transmission of SARS-CoV-2 lineage B.1.1.7 (VOC 2020212/01) is 668 not accounted for by a replicative advantage in primary airway cells or antibody escape. 669 bioRxiv

The SARS-CoV-2 variants associated with infections in India, B.1.617, 671 show enhanced spike cleavage by furin. bioRxiv

Rapid reconstruction of SARS-CoV-2 using a synthetic genomics 674 platform

Mutations that adapt SARS-CoV-2 to mink or ferret do not increase fitness in 676 the human airway

Genomic epidemiology reveals multiple introductions of SARS-CoV-2 679 from mainland Europe into Scotland

The SARS-CoV-2 Spike protein has a broad tropism for mammalian ACE2 682 proteins

Micro-fusion inhibition tests: quantifying antibody neutralization of virus-684 mediated cell-cell fusion

Investigating SARS-CoV-2 surface and air contamination in an acute healthcare 687 setting during the peak of the COVID-19 pandemic in London

Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR

B) Shedding of SARS-CoV-2 viral RNA was determined by E gene RT-qPCR 696 on days 1-10 post-infection. (C) Receptor usage was screened using pseudoviruses expressing the 697 indicated spike proteins into BHK-21 cells expressing the indicated ACE2 protein. Viral entry was 698 measured by assaying luciferase activity (RLU) using the BrightGlo reagent (Promega)

Primary human nasal epithelial cultures (hNECs) were inoculated with Delta or 705 Omicron variants at an MOI of 0.1, and Vero-ACE2-TMPRSS2 (Vero-AT) and Calu-3 cells were 706 inoculated at an MOI of 0.001. Infections were performed in triplicate, back titration confirmed equal 707 inputs of the variants by E gene copies measured by RT-qPCR and infectious units measured by E gene 708 RT-qPCR. Bars show mean + s.d

711 (Green) in vitro and ex vivo. A probe-based RT-qPCR assay was developed to measure the proportion 712 of Omicron and Delta present in mixed samples (see Extended data Figure 3). The proportion of 713 variant-specific signal is shown with the SD of 3 replicates. Equal mixtures were inoculated onto hNECs 714 at a final multiplicity of 0.1 pfu/cell and onto Vero-AT and Calu-3 cells at an MOI of 0.001. Daily 715 harvests were measured for total viral load by E gene qRT-PCR (black dots) and by the variant specific 716 RT-qPCR to give variant proportions. Mean + s.d. of 3 replicates shown. (E) Comparative replication 717 kinetics of SARS-CoV-2 Omicron and Delta isolates and chimeric spike viruses in vitro

Extended data Figure 3 -Extended data of Figure 2B -Design and validation of variant specific 721 multiplexed RT-qPCR and independent isolate repeats. (A) Design schematic of variant specific qPCR 722 primer probe sets for investigating the ratio of Delta to Omicron/BA.1 in competition assays. (B) Design 723 schematic of adapted variant specific qPCR primer probe sets for investigating the ratio of BA.2 to 724 BA.1 in competition assays. (C) Different ratios of Delta and Omicron/BA.1 RNA were mixed and the 725 variant specific RT-qPCR probes, which specifically recognise a region of spike that includes a deletion 726

Extended data Figure 4 -Use of common coronavirus protein receptors and receptor species 729 specificity for SARS-CoV-2 variant entry (A) HEK 293T cells expressing whole SARS-CoV-2 spike were 730 incubated with recombinant hACE2-Fc(IgG) for 30 minutes

DyLight® 650) secondary for 30 minutes, before washing and analysis by flow 732 cytometry. Mean + s.d. of three (N=3) independent repeats plotted. (B, C) Cell-cell fusion assays of 733 BHK cells with rLUC-GFP1-7 expressing the stated spike protein and BHK-21 cells expressing human 734 ACE2 and rLUC-GFP 8-11. All assays were performed in triplicate and are plotted as mean + s

Comparative 738 replication kinetics of SARS-CoV-2 Omicron/BA.1 and Delta variants in primary human nasal epithelial 739 cultures (hNECs) inoculated with Delta or Omicron variants at MOI of 0.1. Cells were pretreated both 740 basolaterally and apically with either 50 µM of Camostat, 1 µM of Amphotericin B or no drug for 2 h 741 prior to infection. 50 µM of Camostat or 1 µM Amphotericin B remained in the basolateral media for 742 the course of the experiment. Infections were performed in triplicate and E gene copy number was 743 determined by RT-qPCR. Plotted as mean of N=3 repeats ± s.d. Experiment performed twice with 744 representative graph shown. (B) Cell-cell fusion assays of Calu-3 cells with rLUC-GFP1-7 expressing the 745 stated spike protein and BHK-21 cells expressing human ACE2 and rLUC-GFP 8-11. All assays were 746 performed in triplicate and are plotted as mean + s.d. Representative repeat shown. (C) Western blot 747 analysis of concentrated pseudovirus expressing different SARS-CoV-2 spike mutants. Levels of 748 lentiviral p24 shown as loading control

for the endosomal pathway, 769 TMPRSS2 pathway, or both, as estimated by fitting a mathematical model to the data. The median 770 estimate and 95% credible interval is reported for each value. The rightmost column shows the p-771 value for the doubling time being different between Omicron and Delta, for each pathway